|
Irinotecan Hydrochloride Clinical Trials
6 actively recruiting trials across 4 locations
▲ +1 trial since June 2026
Also known as: CPT 11, CPT-11, CPT11, Campto, Camptosar +8 more
Pipeline
Phase 1: 1Phase 2: 2Phase 3: 3
Top Sponsors
- UNC Lineberger Comprehensive Cancer Center1
- Sichuan Baili Pharmaceutical Co., Ltd.1
- SWOG Cancer Research Network1
- National Cancer Institute (NCI)1
- NRG Oncology1
Indications
- Cancer6
- Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma1
- Stage II Pancreatic Cancer AJCC v81
- Stage IV Small Intestinal Adenocarcinoma AJCC v81
- Stage IIIB Small Intestinal Adenocarcinoma AJCC v81
Gilbert, Arizona2 trials
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Banner MD Anderson Cancer Center
Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Banner MD Anderson Cancer Center
Phase 3
Other1 trial
Anchorage, Alaska1 trial
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Anchorage Associates in Radiation Medicine
Phase 2
Bethesda, Maryland1 trial
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Institutes of Health Clinical Center
Phase 1
Chapel Hill, North Carolina1 trial
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.